Dihydroartemisinin-Piperaquine Reduces Early Plasmodium vivax Recurrence Compared With Chloroquine

Addressing the Persistence of Plasmodium vivax Malaria

Managing Plasmodium vivax malaria remains a significant clinical challenge due to the parasite's ability to form hypnozoites (dormant liver-stage parasites) that cause multiple relapses [1, 2]. While chloroquine has long been the standard schizontocide (a drug that clears blood-stage parasites), its efficacy is increasingly compromised by emerging resistance, increasing the risk of recurrence when used without antirelapse therapy [3, 4]. Achieving a radical cure (the complete elimination of both blood-stage and liver-stage parasites) requires the addition of primaquine to clear the liver reservoir. However, this 8-aminoquinoline carries a risk of severe hemolysis (premature destruction of red blood cells) in patients with glucose-6-phosphate dehydrogenase deficiency [5, 6]. Furthermore, the standard 14-day primaquine regimen often suffers from poor patient adherence in unsupervised settings, significantly elevating the incidence of recurrence [7]. A recent trial now offers fresh insights into whether dihydroartemisinin-piperaquine (an artemisinin-based combination therapy) can improve early treatment outcomes compared to chloroquine in this complex clinical landscape [8].

Trial Design and Patient Selection in the Amazon Basin

The Curavivax trial was an open-label, single-center, parallel-group, randomized trial conducted at a public reference center for infectious diseases in Manaus, Brazil, located in the Amazon Basin. Between July 5, 2018, and January 13, 2021, researchers screened 1,649 patients to evaluate the efficacy and tolerability of dihydroartemisinin-piperaquine as an alternative schizontocide to traditional chloroquine for treating Plasmodium vivax malaria. This investigation, registered under NCT03208907, focused on addressing the clinical need for effective blood-stage clearance in a region where early recurrences and adherence issues complicate standard care. Eligibility required patients to be older than 6 months and weigh no more than 100 kg, with a diagnosis of P. vivax malaria confirmed by microscopy. To ensure the safe administration of primaquine, participants were required to have glucose-6-phosphate dehydrogenase activity greater than 30% of normal, minimizing the risk of drug-induced hemolytic anemia. A total of 419 patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment arms. The study population consisted of 287 (69%) males and 131 (31%) females. The four specific treatment groups were structured to compare immediate versus delayed antirelapse therapy: chloroquine plus primaquine (n=114), dihydroartemisinin-piperaquine plus primaquine (n=112), chloroquine plus delayed primaquine (n=98), and dihydroartemisinin-piperaquine plus delayed primaquine (n=95). By delaying primaquine administration until day 42 in two of the arms, the researchers could isolate the efficacy of the primary schizontocides in preventing early parasite recurrence. This design provided a rigorous framework for determining whether dihydroartemisinin-piperaquine can effectively manage the initial infection when the standard 14-day primaquine regimen is not immediately initiated.

Comparative Dosing and Treatment Protocols

The Curavivax trial utilized standardized dosing regimens for both the experimental and control arms to ensure a rigorous comparison of schizontocidal efficacy. Patients assigned to the dihydroartemisinin-piperaquine groups received the medication as 40/320 mg or 20/160 mg oral tablets administered once daily for 3 days. In the control groups, chloroquine was administered as 150 mg oral tablets once daily for 3 days. All medications were dosed by bodyweight and dispensed open-label, meaning both the clinicians and the patients were aware of the specific treatment being administered. This 3-day course for both schizontocides (drugs targeting the symptomatic blood-stage of the parasite) reflects the standard duration for clearing active Plasmodium vivax infections. To address the liver-stage hypnozoites responsible for future relapses, the researchers incorporated primaquine into the treatment protocols. Primaquine was administered as 15 mg oral tablets once daily for 14 days, with the timing of the regimen serving as a critical variable in the study design. Participants were randomized to either initiate primaquine on day 0, concurrent with the start of the schizontocide, or to have the antirelapse therapy delayed until day 42. By delaying the 14-day primaquine course, the investigators were able to specifically measure the ability of dihydroartemisinin-piperaquine and chloroquine to prevent early recurrence without the confounding effect of immediate liver-stage clearance.

Efficacy and Early Recurrence Prevention

The researchers established the primary outcome as the recurrence rate at day 42 within the per-protocol population, which included only those participants who completed the treatment exactly as assigned. In the final analysis, the investigators excluded one patient from the chloroquine plus primaquine group due to a severe protocol deviation. When evaluating the groups that received immediate antirelapse therapy, the day 42 recurrence rate for chloroquine plus primaquine was 2.0% (95% CI 0.2 to 7.0), while the rate for dihydroartemisinin-piperaquine plus primaquine was 1.0% (95% CI 0.0 to 5.3). This difference did not reach statistical significance, as evidenced by a hazard ratio of 0.48 (95% CI 0.00 to 40209.06; p=0.44), suggesting that both regimens are highly effective when combined with immediate primaquine administration. The clinical utility of dihydroartemisinin-piperaquine became most apparent in the groups where primaquine was delayed, a scenario that mimics real-world challenges with medication adherence or contraindications. For patients receiving only the initial blood-stage treatment, the day 42 recurrence rate for dihydroartemisinin-piperaquine alone was 2.4% (95% CI 0.3 to 8.5). In stark contrast, the recurrence rate for chloroquine alone was 27.3% (95% CI 18.3 to 37.8). Statistical analysis confirmed that dihydroartemisinin-piperaquine alone was significantly more effective than chloroquine alone for preventing early recurrence, with a hazard ratio of 0.08 (95% CI 0.00 to 0.22; p<0.0001). These data indicate that dihydroartemisinin-piperaquine provides a substantial prophylactic window, suppressing the emergence of blood-stage parasites even when the liver-stage reservoir has not yet been cleared by primaquine.

Safety Profile and Clinical Utility

The investigators assessed safety in all participants who received at least one dose of the study medication, monitoring for adverse events throughout the follow-up period. The researchers reported that all treatment regimens were well tolerated by the participants, with no significant differences in the safety profile between those receiving the standard chloroquine regimen and those treated with dihydroartemisinin-piperaquine. This high level of tolerability is a critical finding for clinicians, as it suggests that transitioning to this artemisinin-based combination therapy does not increase the risk of treatment discontinuation due to side effects. The clinical utility of these findings is particularly relevant in regions where operational challenges hinder adherence to the 14-day primaquine regimen or where chloroquine resistance is emerging. Because dihydroartemisinin-piperaquine effectively suppressed early recurrence even when primaquine was delayed until day 42, it provides a highly reliable schizontocidal (blood-stage parasite clearing) effect. For the practicing physician, this means that dihydroartemisinin-piperaquine offers a robust therapeutic window, reducing the risk of early clinical failure in patients who may struggle with the long-term antirelapse therapy required to clear dormant liver-stage parasites. The study authors conclude that the high therapeutic efficacy and prevention of early recurrence support the use of dihydroartemisinin-piperaquine for Plasmodium vivax treatment across Latin America.

References

1. Rajasekhar M, Simpson JA, Ley B, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.. The Lancet. Infectious diseases. 2024. doi:10.1016/S1473-3099(23)00431-0

2. Commons RJ, Rajasekhar M, Edler P, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases. 2023. doi:10.1016/s1473-3099(23)00430-9

3. Commons RJ, Simpson JA, Thriemer K, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. The Lancet Infectious Diseases. 2018. doi:10.1016/s1473-3099(18)30348-7

4. Naing C, Racloz V, Whittaker M, et al. Efficacy and Safety of Dihydroartemisinin-Piperaquine for Treatment of Plasmodium vivax Malaria in Endemic Countries: Meta-Analysis of Randomized Controlled Studies. PLoS ONE. 2013. doi:10.1371/journal.pone.0078819

5. Chu CS, Bancone G, Moore KA, et al. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Medicine. 2017. doi:10.1371/journal.pmed.1002224

6. Yilma D, Groves ES, Brito-Sousa JD, et al. Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses. American Journal of Tropical Medicine and Hygiene. 2023. doi:10.4269/ajtmh.23-0280

7. Poespoprodjo JR, Burdam FH, Candrawati F, et al. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. The Lancet Infectious Diseases. 2021. doi:10.1016/s1473-3099(21)00358-3

8. Baía-da-Silva DC, Machado KVA, Rabelo ALR, et al. Dihydroartemisinin-piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial.. The Lancet. Infectious diseases. 2026. doi:10.1016/S1473-3099(26)00139-8